Menu
Back to User profile » Dr Yuanyuan Zhao
Papers published by Dr Yuanyuan Zhao:
Practices and Hindrances in Cancer Pain Management: Results of a National Multi-Cancer Center Survey Among Healthcare Professionals in China
Su C, Chen M, Chen G, Li Y, Li N, Hu Z, Hu X, Zhao Y, Yu Q, Jiang W
Cancer Management and Research 2021, 13:1709-1717
Published Date: 18 February 2021
Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma
Zhao YY, Tian Y, Liu L, Zhan JH, Hou X, Chen X, Zhou T, Huang Y, Zhang L
Drug Design, Development and Therapy 2018, 12:2655-2663
Published Date: 29 August 2018
A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma
Zhao YY, Liu L, Zhou T, Zhou NN, Yang YP, Hou X, Li Y, Zhao HY, Huang Y, Zhang L
OncoTargets and Therapy 2016, 9:6915-6920
Published Date: 8 November 2016
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
Xue C, Tian Y, Zhang J, Zhao YY, Zhan JH, Fang WF, Zhang L
Drug Design, Development and Therapy 2016, 10:1299-1306
Published Date: 31 March 2016
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L
Drug Design, Development and Therapy 2016, 10:1173-1180
Published Date: 15 March 2016
Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase
Qin T, Zhou NN, Zeng YD, Dinglin XX, Zhao YY, Liu H, Chen LK
OncoTargets and Therapy 2016, 9:1095-1103
Published Date: 1 March 2016
Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L
Drug Design, Development and Therapy 2015, 9:4897-4907
Published Date: 26 August 2015
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
Zhang XK, Qin T, Zeng YD, Zhao YY, Hou X, Fang WF, Hong SD, Zhou T, Hu ZH, Yang YP, Ma YX, Xue C, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2015, 8:1219-1227
Published Date: 26 May 2015
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L
Drug Design, Development and Therapy 2014, 8:1827-1837
Published Date: 10 October 2014
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
Hong SD, Fang WF, Liang WH, Yan Y, Zhou T, Qin T, Wu X, Ma YX, Zhao YY, Yang YP, Hu ZH, Xue C, Hou X, Chen Y, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2014, 7:1851-1867
Published Date: 7 October 2014
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
Wu X, Liang WH, Hou X, Lin Z, Zhao HY, Huang Y, Fang WF, Zhao YY, Wu JX, Yang YP, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Zhou T, Qin T, Zhang L
OncoTargets and Therapy 2013, 6:1481-1491
Published Date: 21 October 2013
The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution
Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H
OncoTargets and Therapy 2012, 5:349-355
Published Date: 15 November 2012